As I see it

Share this article:
Another bad idea from government policy wonks surfaced in July when an FDA enforcement director told the Wall Street Journal his agency is using press releases as a vehicle for serving notice on certain companies that they are out of compliance with regulations, and to get their acts together.

David Elder told the WSJ that it was wrong to judge his agency's performance by the number of Warning Letters to industry it issues. These have been dwindling for years.

The FDA has other ways of bringing its enforcement concerns to industry's attention, he said. The newspaper quoted him as saying that rather than sending out individual Warning Letters to separate companies with a similar violation, the FDA now alerts the industry via press releases when it notices problems. Challenged later about the legal adequacy of a press release as a formal FDA warning, Elder referred us to the FDA Press Office, which issued a vaguely worded statement that press releases “can be an effective way to communicate to our various audiences our position or views and perhaps in some instances may help industry avoid regulatory action by understanding the FDA's position and how they can meet their regulatory obligations.”

While this might have been an example of the FDA not wanting to upset the WSJ by directly casting aspersions on the accuracy of the way it reported Elder, it equally might have been a way of back-pedaling on the whole strategy. With newspaper circulations tumbling throughout the nation, and TV news viewership in decline, this is no time for the FDA to be adopting a new policy of serving regulatory notice via news releases. There's no guarantee its releases will be published, much less reach target companies who could claim ignorance as an excuse. It makes you wonder how such ideas get off the ground.

Dickinson is editor of Dickinson's FDA Webview (fdaweb.com)
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in As I See It

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in As I See It

As I See It: Patient Centricity

As I See It: Patient Centricity

A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive

As I See It: FDA's social-media moves

As I See It: FDA's social-media moves

FDA has insisted that its antique regulations can address every new promotional challenge

As I See It: FDA and marketing materials

As I See It: FDA and marketing materials

The more clarity that FDA provides, the more confident companies can be in their medical communications